AXSM * Stock Overview
A biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Axsome Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,519.00 |
| 52 Week High | US$1,519.00 |
| 52 Week Low | US$1,190.00 |
| Beta | 1.25 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 115.46% |
| 5 Year Change | n/a |
| Change since IPO | 141.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXSM * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -0.5% |
| 1Y | n/a | -19.4% | -6.6% |
Return vs Industry: Insufficient data to determine how AXSM * performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AXSM * performed against the MX Market.
Price Volatility
| AXSM * volatility | |
|---|---|
| AXSM * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: AXSM *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine AXSM *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 589 | Herriot Tabuteau | www.axsome.com |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Axsome Therapeutics, Inc. Fundamentals Summary
| AXSM * fundamental statistics | |
|---|---|
| Market cap | Mex$79.53b |
| Earnings (TTM) | -Mex$5.98b |
| Revenue (TTM) | Mex$5.65b |
14.1x
P/S Ratio-13.3x
P/E RatioIs AXSM * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXSM * income statement (TTM) | |
|---|---|
| Revenue | US$291.49m |
| Cost of Revenue | US$28.26m |
| Gross Profit | US$263.23m |
| Other Expenses | US$571.78m |
| Earnings | -US$308.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.43 |
| Gross Margin | 90.30% |
| Net Profit Margin | -105.85% |
| Debt/Equity Ratio | 174.4% |
How did AXSM * perform over the long term?
See historical performance and comparison